263 related articles for article (PubMed ID: 18331271)
1. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Miner M; Billups KL
J Sex Med; 2008 May; 5(5):1066-1078. PubMed ID: 18331271
[TBL] [Abstract][Full Text] [Related]
2. Vardenafil in men with stable statin therapy and dyslipidemia.
Miner M; Gilderman L; Bailen J; Cook D; Dawson K; Stanislaus M; Beresford E; Barnes A
J Sex Med; 2008 Jun; 5(6):1455-67. PubMed ID: 18373526
[TBL] [Abstract][Full Text] [Related]
3. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Nehra A
Mayo Clin Proc; 2009 Feb; 84(2):139-48. PubMed ID: 19181648
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
5. Statins and erectile dysfunction: a critical summary of current evidence.
La Vignera S; Condorelli RA; Vicari E; Calogero AE
J Androl; 2012; 33(4):552-8. PubMed ID: 22052777
[TBL] [Abstract][Full Text] [Related]
6. The role of statins in erectile dysfunction.
Ferrer E; Moral MA; Bozzo J
Drugs Today (Barc); 2007 Jan; 43(1):55-9. PubMed ID: 17315053
[TBL] [Abstract][Full Text] [Related]
7. The role of statins in erectile dysfunction: a systematic review and meta-analysis.
Cai X; Tian Y; Wu T; Cao CX; Bu SY; Wang KJ
Asian J Androl; 2014; 16(3):461-6. PubMed ID: 24556747
[TBL] [Abstract][Full Text] [Related]
8. Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes.
Palumbo PJ
Am J Med Sci; 2007 Dec; 334(6):466-80. PubMed ID: 18091369
[TBL] [Abstract][Full Text] [Related]
9. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Sommer F; Schulze W
World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia as a risk factor for erectile dysfunction.
Vrentzos GE; Paraskevas KI; Mikhailidis DP
Curr Med Chem; 2007; 14(16):1765-70. PubMed ID: 17627514
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Goldstein I; Kim E; Steers WD; Pryor JL; Wilde DW; Natanegara F; Wong DG; Ahuja S
J Sex Med; 2007 Jan; 4(1):166-175. PubMed ID: 17233782
[TBL] [Abstract][Full Text] [Related]
12. Endothelial effects of drugs designed to treat erectile dysfunction.
Aversa A; Caprio M; Rosano GM; Spera G
Curr Pharm Des; 2008; 14(35):3768-78. PubMed ID: 19128229
[TBL] [Abstract][Full Text] [Related]
13. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine.
Jackson G; Rosen RC; Kloner RA; Kostis JB
J Sex Med; 2006 Jan; 3(1):28-36; discussion 36. PubMed ID: 16409215
[TBL] [Abstract][Full Text] [Related]
14. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia.
Ng CF; Lee CP; Ho AL; Lee VW
J Sex Med; 2011 Oct; 8(10):2883-93. PubMed ID: 21810191
[TBL] [Abstract][Full Text] [Related]
15. Erectile dysfunction: interrelationship with the metabolic syndrome.
Matfin G; Jawa A; Fonseca VA
Curr Diab Rep; 2005 Feb; 5(1):64-9. PubMed ID: 15663920
[TBL] [Abstract][Full Text] [Related]
16. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
Hellstrom WJ
Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
Blonde L
Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
Ganz P
Am J Cardiol; 2005 Dec; 96(12B):8M-12M. PubMed ID: 16387559
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
20. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.
Vicari E; La Vignera S; Condorelli R; Calogero AE
J Sex Med; 2010 Mar; 7(3):1247-53. PubMed ID: 19674252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
